Seroepidemiological and Microbiological Study of Brucellosis in Kuwait

Ts, Dimitrov; Panigrahi, D; Emara, Mahmoud; Awni, F.; Passadilla, R.

doi:10.1159/000078319

Cited by 18 publications

(21 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 32%of positive blood cultures found in this study are within the 15–90% range reported in previous studies [1,14]. Differences in isolation rates between centers may be due to delay in diagnosis and previous antibiotic usage of the patients before admission to clinics.…”

Section: Discussionsupporting

confidence: 73%

Clinical, Diagnostic and Therapeutic Approaches to Complications of Brucellosis: An Experience of 12 Years

et al. 2011

View full text Add to dashboard Cite

Objective: To describe the clinical presentations, laboratory findings, prevalence and pattern of complications and the response to treatment of brucellosis in a 12-year period in a Turkish research hospital. Materials and Methods: Between 1996 and 2008, 231 patients were diagnosed with brucellosis and treated in our clinic. Medical records of 189 of the 231 patients with at least one demonstrable complication of the disease were reviewed for anamnesis, diagnosis, complications, treatment and clinical outcomes. Results: The decreasing order of the complications was: hematological, 104 (55%); osteoarticular, 70 (37%); hepatobiliary, 59 (31%), and gastrointestinal, 23 (12%). The most common laboratory findings were anemia, lymphomonocytosis, elevated sedimentation rate and C-reactive protein, and elevated aminotransaminases. Conclusion: The hematological, osteoarticular and hepatobiliary manifestations were predominant. Bursitis, synovitis, glomerulonephritis, cutaneous lesion and deep vein thrombosis were the rare complications observed in our study. In clinical practice, brucellosis should be considered in the differential diagnosis in the presence of infrequent complications.

show abstract

Section: Discussionsupporting

confidence: 73%

Clinical, Diagnostic and Therapeutic Approaches to Complications of Brucellosis: An Experience of 12 Years

et al. 2011

View full text Add to dashboard Cite

show abstract

“…The agent PD 131628 was the only quinolone for which no crossresistance of a ciprofloxacin-resistant strain was found in another study by Qadri et al (50), although an increased MIC for the drug was noted against this strain. On the other hand, in two recent studies, one from Turkey (13) and one from Kuwait (21), all isolates were susceptible to ciprofloxacin, whereas 9.6% and 8% of the isolates were resistant to rifampin in vitro, respectively.…”

Section: Laboratory Studiesmentioning

confidence: 82%

“…Thus, it will not be surprising if resistance of Brucella melitensis to quinolones will increase as well in the future. It should also be noted that resistance of Brucella to rifampin may represent an issue for consideration, judging by the results of some recent in vitro studies (13,21). As Baykam et al have also commented (13), this fact may be linked to the increased use of rifampin in some areas due to the reemergence of tuberculosis.…”

Section: Critical Evaluation Of the Available Evidencementioning

confidence: 99%

Quinolones for Treatment of Human Brucellosis: Critical Review of the Evidence from Microbiological and Clinical Studies

Falagas

Bliziotis

2006

Antimicrob Agents Chemother

View full text Add to dashboard Cite

3Brucellosis is a zoonotic disease with worldwide distribution that is endemic in the Mediterranean region, the Middle East, Central Asia, and parts of Africa and Latin America. Worldwide, brucellosis remains a major cause of morbidity in humans and domesticated animals. In animals, bovine brucellosis, caused mainly by Brucella abortus, is still the most widespread form. In humans, ovine/caprine brucellosis caused by Brucella melitensis is by far the most common type of disease. The disease has a wide spectrum of clinical manifestations and can affect a variety of organs and systems. Localized and complicated forms of brucellosis cause important morbidity and require prolonged medical treatment. Fortunately, mortality is relatively low and is related mainly to cardiovascular and central nervous system complications of the disease.Although several studies have been conducted over the past 2 decades, there is no conclusive evidence on the optimum antibiotic therapy for brucellosis. Disease relapse still represents one of the most important therapeutic problems. The last recommendation by the World Health Organization (WHO) for the treatment of acute brucellosis in adults was published in 1986 and suggested 600 to 900 mg rifampin and 200 mg doxycycline daily for a minimum of 6 weeks (8). Alternatively, the WHO suggested that rifampin could be replaced with 15 mg/kg of streptomycin, administered intramuscularly for only 2 weeks. However, a meta-analysis, as well as a prospective randomized trial, both performed by Solera et al., showed that the "good old" combination regimen of streptomycin with an oral tetracycline results in fewer relapses than the doxycycline-rifampin combination (57, 58). Controlled clinical trials with other antibiotics, including trimethoprim-sulfomethoxazole, new macrolides, and ␤-lactams, have shown inferior results or involved too few patients for a proper evaluation. Thus, the most widely used regimens are the two aforementioned combinations that were recommended by the WHO. In addition, rifampin monotherapy is the main option for brucellosis during pregnancy, whereas its combination with trimethoprim-sulfomethoxazole is the suggested treatment for childhood brucellosis (5, 34).Certain focal forms of brucellosis are difficult to treat, and surgery should be considered for patients with endocarditis or cerebral, epidural, splenic, or other abscesses (20, 41). Regarding medical treatment, although the antibiotics used are essentially the same, prolonged therapy, up to six or more months, may be needed for patients with osteoarticular forms of the disease, and especially spondylitis (18,56,65). Also, tripleantibiotic combinations were found to be of value in some case series of brucellar endocarditis, spondylitis, and meningitis (2, 41, 65). Relapse of the disease also represents a major therapeutic problem for its focal forms.Since the mid 1980s, laboratory researchers and clinicians have performed several microbiological and clinical studies of the possible use of quinolones in the treatmen...

show abstract

“…Intermediate rifampin susceptibility elsewhere in Turkey has been described previously (1). Limited in vitro susceptibility to rifampin and trimethoprim-sulfamethoxazole in Kuwait (5) and Mexico (9) has similarly been reported.…”

mentioning

confidence: 94%

Antimicrobial Susceptibility ofBrucella melitensisIsolates in Peru

Maves

Castillo

Guillén³

et al. 2011

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Brucellosis is an important public health problem in Peru. We evaluated 48 human Brucella melitensis biotype 1 strains from Peru between 2000 and 2006. MICs of isolates to doxycycline, azithromycin, gentamicin, rifampin, ciprofloxacin, and trimethoprim-sulfamethoxazole were determined by the Etest method. All isolates were sensitive to tested drugs during the periods of testing. Relapses did not appear to be related to drug resistance.

show abstract

Seroepidemiological and Microbiological Study of Brucellosis in Kuwait

Cited by 18 publications

References 12 publications

Clinical, Diagnostic and Therapeutic Approaches to Complications of Brucellosis: An Experience of 12 Years

Clinical, Diagnostic and Therapeutic Approaches to Complications of Brucellosis: An Experience of 12 Years

Quinolones for Treatment of Human Brucellosis: Critical Review of the Evidence from Microbiological and Clinical Studies

Antimicrobial Susceptibility ofBrucella melitensisIsolates in Peru

Contact Info

Product

Resources

About